<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetrahydrozoline (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetrahydrozoline (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tetrahydrozoline (nasal): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12318" href="/d/html/12318.html" rel="external">see "Tetrahydrozoline (nasal): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9600163"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Adrenergic Agonist Agent;</li>
<li>
                        Decongestant;</li>
<li>
                        Imidazoline Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F9600130"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Nasal congestion: Intranasal:</b> Instill 2 to 4 drops or 3 to 4 sprays of 0.1% solution into each nostril every 3 to 4 hours as needed, no more frequently than every 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Duration:</i> Generally, limit to 3 to 5 days of consecutive use due to risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227','lexi-content-ref-25644617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227','lexi-content-ref-25644617'])">Ref</a></span>). In patients with persistent symptoms despite use of first-line therapies, some guidelines suggest intranasal decongestants may be offered in combination with an intranasal corticosteroid for up to 4 weeks with low risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doe drugH1Div" id="F9600131"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9600129"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b> Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2-6 years: Instill 2-3 drops of 0.05% solution into each nostril every 4-6 hours as needed, no more frequently than every 3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;6 years: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F9600038"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Sneezing, stinging sensation of the nose</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p></div>
<div class="block coi drugH1Div" id="F9605851"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tetrahydrozoline or any component of the formulation. The 0.5% solution is contraindicated in children &lt;2 years of age. The 0.1% solution is contraindicated in children &lt;6 years of age.</p></div>
<div class="block war drugH1Div" id="F9605852"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Somnolence: Profound sedation may occur in children following overdose. This may be accompanied by diaphoresis, hypotension, and/or shock. Do not exceed recommended dosages.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension and coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Endocrine disorders: Use with caution in patients with endocrine disorders, including diabetes and hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: For intranasal use only.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">•	 Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1-2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication, 2012).</p></div>
<div class="block geq drugH1Div" id="F9600035"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F9600152"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tyzine Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (15 mL): $91.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>
<div class="block use drugH1Div" id="F9600036"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Symptomatic relief of nasal congestion</p></div>
<div class="block mst drugH1Div" id="F15801080"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300127"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9600112"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Tetrahydrozoline (Nasal).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: Decongestants (Nasally Administered) may decrease the serum concentration of Zavegepant.  Management: Avoid the concurrent administration of intranasal decongestants with zavegepant. If combined use is unavoidable, intranasal decongestants should be administered at least 1 hour after zavegepant administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F9887149"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block mop drugH1Div" id="F9625213"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, symptom response</p></div>
<div class="block pha drugH1Div" id="F9600123"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction</p></div>
<div class="block phk drugH1Div" id="F9600124"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Onset of action: Decongestant: 4-8 hours</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrahydrozoline-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U.S. Food and Drug Administration. October 25, 2012. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm</a>. Accessed September 5, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1)(suppl):S1-S43. doi:10.1177/0194599814561600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrahydrozoline-nasal-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9935 Version 106.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
